Most antidepressants are ineffective for children and teenagers and some can even be harmful, according to a report in The Lancet.
Researchers who looked at 14 drugs found that only Eli Lilly's Prozac (fluoxetine) was more effective than placebo at relieving symptoms of depression in young people.
They found that Pfizer's Effexor (venlafaxine) was associated with an increased risk of suicidal thoughts and suicide attempts when compared to placebo and five other antidepressants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze